Universities of Lille

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Retrieved on: 
понедельник, января 29, 2024
Drug, Conditional sentence, Spark Therapeutics, Translation, Patient, Therapy, Employment, Paratriathlon, AAV, Universities of Lille, Innovation, Pfizer, LUNA, AMD, Adverum Biotechnologies, Drug discovery, CNS, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
  • “On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team.
  • Dr. Corbau joins Adverum from GenEdit, where he served as Chief Scientific Officer.
  • Prior to joining GenEdit, Dr. Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline, a clinical stage company developing AAV-vector mediated systemic gene therapies for chronic diseases.

Neoplants Bioengineers Houseplants to Remove Harmful Air Pollutants

Retrieved on: 
четверг, октября 27, 2022
Retail, Other Natural Resources, Environment, Natural Resources, Green Technology, Specialty, Environmental Health, Volatile organic compound, Lung cancer, Neo, United States Environmental Protection Agency, EPA, Houseplant, Chronic obstructive pulmonary disease, Plant, Toluene, COPD, Nature, CTO, Heart, Solution, Climate change, VOC, Formaldehyde, Universities of Lille, Technology, Benzene, Shell, Bachelor of Engineering, Doctor of Philosophy, Engineering, World Health Organization, Partnership, Death, Research, Paint, Atmosphere, Recycling, Stroke, Intention, World, Adhesive, Moyamoya disease, Pollutant, Environment, Air pollution, Environmental remediation, Management, Renewable energy

For too long, the advance of technology has been at the expense of our environment, said Lionel Mora, Neoplants CEO and co-founder.

Key Points: 
  • For too long, the advance of technology has been at the expense of our environment, said Lionel Mora, Neoplants CEO and co-founder.
  • Neoplants uses bioengineering and directed evolution to create Plants with a Purpose, beginning with the first plant built to fight air pollution: Neo P1.
  • The worlds most efficient natural air purification system, the Neo P1, is more effective than up to thirty of the most popular houseplants in capturing and recycling harmful VOCs from indoor air.
  • Neoplants is backed by leading investors and advisors, including True Ventures, Heartcore, Collaborative Fund and Entrepreneur First.

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Retrieved on: 
понедельник, августа 8, 2022
Social conditions in Honduras, Headquarters, China Media Group Headquarters, CEO, Universities of Lille, Leadership, Research, Environment, Pfizer, Compliance, Suzhou Industrial Park, BMS, Patient, Discovery, Process, Early, HKEX, Therapy, Safety, Drug development, Novartis, Nature, Breast disease, News, AstraZeneca, MD, Medicine, ICB, Bristol Myers Squibb, Pharmaceutical industry, Medical device, Ribociclib, Neratinib

Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.

Key Points: 
  • Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.
  • During her time at AstraZeneca, Dr. Germa built an Early Development Clinical Group with over 180 staff and guided the clinical development of the early oncology portfolio.
  • "I would like to express my warmest welcome to Dr. Germa on her appointment," said Dr. Xueming Qian, CEO of Transcenta.
  • I am thrilled to join Transcenta at this important juncture," said Dr. Caroline Germa, Executive Vice President, Global Medicine Development and Chief Medical Officer of Transcenta.